It is therefore not surprising that restoring the Bcl-2 family balance has been pinpointed as strategy for overcoming the apoptosis defects of CLL cells, as witnessed by the recent approval of the Bcl-2 selective inhibitor Venetoclax for CLL treatment (7, 8). Here, BCL2 is linked to B-cell chronic lymphocytic leukemia.